MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
2.830
+0.200
+7.60%
Closed 17:54 05/13 EDT
OPEN
2.640
PREV CLOSE
2.630
HIGH
2.978
LOW
2.550
VOLUME
871.86K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
1.450
MARKET CAP
93.95M
P/E (TTM)
-0.9148
1D
5D
1M
3M
1Y
5Y
1D
Lexeo Therapeutics GAAP EPS of -$0.99 misses by $0.18
Seeking Alpha · 19h ago
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 22h ago
Lexeo Therapeutics Price Target Cut to $20.00/Share From $22.00 by Chardan Capital
Dow Jones · 22h ago
Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $20
Benzinga · 22h ago
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital
TipRanks · 23h ago
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion
TipRanks · 1d ago
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan
TipRanks · 1d ago
Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 1d ago
More
About LXEO
More
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Recently
Symbol
Price
%Change

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.